Mylan ranks among the leading generic and specialty pharmaceutical companies in the world and maintains one of the industry’s broadest and highest quality portfolios. With more than 1,400 high quality generic, branded and over-the-counter products, we cover virtually every dosage form and therapeutic category, from cardiovascular, osteoporosis and gastro-intestinal diseases, to central nervous system, antihistamines, diabetes and antibacterial. Our global workforce is more than 30,000 strong and we serve customers and patients in 165 countries and territories, as part of our mission to provide quality health care to the world’s 7 billion people, one person at a time.
In Europe, Mylan has operations in 38 countries with more than 6,800 employees. Our sales team alone in Europe is 1,950 people strong, serving pharmacists (retail and hospital), physicians, wholesalers and consumers.
In Europe, our key therapeutic areas include:
- Women’s health
- HIV / AIDS
- Influenza Vaccines
In Ireland, Mylan is currently the largest employer in generic pharmaceuticals. Three successful decades of working with the country’s skilled and highly educated workforce, together with a shared work ethic and commitment to excellence, has helped us maintain our strong local footprint. Our most recent Irish expansion outlined an annual investment of up to €76 million ($100 million), including funding for expanded research and development (R&D) capabilities, such as our Respiratory R&D pilot facilities in Dublin, as well as support from the Irish government, through IDA and Údarás na Gaeltacht.
Welcoming Mylan‘s announcement of our most recent expansion in Ireland, Enda Kenny T.D., Taoiseach, said: “Mylan’s decision to expand in both Dublin and Galway is most welcome news. Mylan is a key member of the Irish pharmaceutical sector and one of the top suppliers in the country, providing the market with high quality generic pharmaceuticals and over-the-counter medicines. Today’s announcement, in addition to the company’s proven, 25-year track record as a top employer and reliable exporter in Ireland, demonstrates Mylan’s commitment to its Irish operations and recognition for the capabilities of its talented workforce. I would like to offer continued support of the Irish government, and IDA Ireland, to Mylan as it continues to grow in our country and as it further serves as an innovative contributor to the Irish economy.’’
Our Irish facilities and workforce of over 1,000 employees and 27 nationalities are located in Dublin and Galway. They uniquely represent a microcosm of the diverse global Mylan health care offering, all in one country.
Our three Dublin facilities, namely the Mylan Ireland Centre of Excellence, Mylan Dublin Respiratory and Mylan Dublin (Oral Solid Dosage), employ 800 passionate and unconventional leaders, in departments ranging from Respiratory product, process and device development to Supply Chain, Quality and Manufacturing.
Mylan Ireland’s global Centre of Excellence, located on Dublin’s Malahide Road, is our regional hub for a variety of business functions, some of which include, Global Supply Chain, Sales & Marketing, Sourcing, Master Data, Quality, Product Launch, IT and HR. This strategic centre plays a significant role optimising efficiencies to support Mylan’s continuing global growth and innovation. Occupying over 3,700 sq. metres over five floors close to Dublin Airport, our modern, state-of-the-art office building is home to qualified and committed pharmaceutical professionals from all over the world.
Dublin is also home to Mylan’s Respiratory Research & Development (R&D) Pilot plant, and following the granting of full planning permission, construction of Mylan’s only dry-powder inhaler commercial facility is underway. This site will develop and commercialise a portfolio of high quality and complex branded and generic inhaled products, improving patient’s global access to respiratory medicines. This investment in Mylan’s Irish operations and the growth of our capabilities in the country, demonstrate our continued commitment to and confidence in our respiratory franchise, which is among Mylan’s many long-term growth drivers.
Mylan Dublin was founded in 1985. Trading as Gerard Laboratories, the Oral Solid Dose (OSD) Pharmaceuticals manufacturing site joined the Mylan family in 2007. The facility is HPRA (Health Products Regulatory Authority), FDA (U.S. Food and Drug Administration) and ANVISA (National Health Surveillance Agency of Brazil) approved and currently supplies EMEA, Canada, Australia and New Zealand. At the site’s location in Baldoyle, North Dublin, we completed an OSD granulation expansion in 2013 and a laboratory expansion in late 2014. The site expects to produce 3.7 billion doses and 57 million packs in 2015 and currently employs over 400 people to support OSD operations.
Mylan Galway began its journey in 1982, when a manufacturing facility for aseptic glass ampoule filling was set up in Inverin, half an hour’s drive from Galway city. In 1991 Canadian company Bioniche Life Sciences Inc. acquired the business and vial and syringe aseptic filling was introduced. The Galway facility became part of the Mylan family in 2010 and Mylan Teoranta came into being in January 2013.
As the largest employer in the Galway Gaeltacht, and supported by Údarás na Gaeltachta, our team’s focus there is on composite and unique products for the international market. We develop and manufacture high quality, sterile injectable products for Mylan Institutional, suitable for a range of therapeutic categories including oncology, cardiovascular, anti-infectives and anesthesia/pain management. Pharmaceutical products filled in vials are exported to the U.S. and Canada. Two Medical Devices are manufactured in Galway, both devices contain Hyaluronic Acid and are presented in vial and syringe format, one for the treatment of interstitial cystitis and the other for the treatment of muscular/skeletal inflammation and pain. These products are exported worldwide, with the exception of the U.S.
The Mylan Institutional business provides pharmaceutical products and services to institutional customers in the U.S.A., including hospitals, clinics and long-term care facilities. Mylan Teoranta is approved by the FDA (U.S. Food and Drug Administration) and the HPRA (Health Products Regulatory Authority), and is regulated to the ISO 13485 standard. Mylan continues to invest in the Galway site with the expansion of our Manufacturing, Packaging and Quality Control Laboratories, due for completion by the end of 2015.